Oruka Therapeutics, Inc. ORKA Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price?
- Oruka Therapeutics, Inc. (ORKA) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price of $18.66 in Q1 2026.
- How has Oruka Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price changed year-over-year?
- Oruka Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price increased by 56.0% year-over-year, from $11.96 to $18.66.